|
Symbol
|
RMABXV | YOTLTQ | LTHCLK | AAIETQ | AAXSTQ | RMA3QV | LJSULK | ABSFTQ | CQWBKB | LXWCLK | SKS6LK | QDPRCH | ADRATQ | LZQRCH | ADSXTQ | RMBU5V | QZKRCH | AECRTQ | RCDRCH | RMBFBV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nom | Multi Vonti | Worst of Callable Reverse Convertible | LUKB Softcallable Multi Reverse Convertible | Worst of Reverse Convertible | Worst of Reverse Convertible | Multi Vonti | LUKB Multi Reverse Convertible | Worst of Reverse Convertible | Reverse Convertible | LUKB Multi Reverse Convertible | LUKB Softcallable Multi Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Reverse Convertible | Multi Vonti | Worst of Callable Reverse Convertible | Worst of Reverse Convertible | Autocallable Reverse Convertible | Multi Vonti |
|
Sous-jacent
|
Nestlé S.A. / Novartis AG / Roche PS | Nestlé S.A. / Novartis AG / Roche PS | ABB / Nestlé S.A. / Novartis AG / Roche PS / Swiss RE AG | Nestlé S.A. / Novartis AG / Roche PS | Compagnie Financière Richemont SA / Nestlé S.A. / Novartis AG / Roche PS / UBS Group AG | Alcon / Lonza Group N / Novartis AG / Roche PS / Sandoz Group AG | Nestlé S.A. / Novartis AG / Roche PS / Swisscom N | ABB / Nestlé S.A. / Novartis AG / Roche PS / UBS Group AG | Lonza Group N / Novartis AG / Roche PS / Straumann Hldg. AG | Nestlé S.A. / Novartis AG / Roche PS / Swisscom N | Galderma Group AG / Novartis AG / Sika AG | Nestlé S.A. / Novartis AG / Roche PS / Zurich Insurance Group AG | ABB / Nestlé S.A. / Novartis AG / Roche PS / UBS Group AG | Givaudan / Novartis AG / Sandoz Group AG | Nestlé S.A. / Novartis AG / Roche PS | Lonza Group N / Novartis AG / Straumann Hldg. AG / Ypsomed Hldg. AG | Lonza Group N / Novartis AG / Roche PS / Sandoz Group AG | Compagnie Financière Richemont SA / Nestlé S.A. / Novartis AG / Roche PS / Zurich Insurance Group AG | Novartis AG / Roche PS / Swiss Life Hldg. N / Swiss RE AG / Zurich Insurance Group AG | Kühne & Nagel Intl. AG / Novartis AG / Sika AG |
|
Emetteur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Échéance
|
12.10.2026 | 24.11.2027 | 09.07.2027 | 19.07.2027 | 13.09.2027 | 09.11.2026 | 19.11.2026 | 20.12.2027 | 13.03.2028 | 25.03.2027 | 07.04.2027 | 16.05.2028 | 04.08.2028 | 07.08.2029 | 11.08.2028 | 22.02.2027 | 08.09.2026 | 25.09.2028 | 26.09.2028 | 04.10.2027 |
| Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Prix d'exercise
|
77,13 | 74,2425 | 58,7776 | 52,063 | 43,77 | 56,14 | 62,176 | 37,59 | 78,705 | 76,296 | 174,48 | 65,7375 | 35,72 | 2 627,25 | 46,384 | 70,63 | 425,25 | 281,20 | 97,685 | 130,88 |
| rendement max. p.a. | 15,87% | 6,84% | 4,66% | 0,99% | 1,99% | 16,42% | -1,45% | 1,92% | 8,37% | 7,76% | 11,44% | 5,54% | 3,30% | 5,38% | 2,36% | 4,55% | - | 3,46% | 4,50% | 2,94% |
| Demande | 98,50 | 99,00 | - | 100,93 | 101,39 | 97,50 | - | 101,44 | 95,70 | - | - | 98,18 | 99,54 | 97,17 | 100,35 | 99,20 | - | 99,06 | 100,99 | 100,30 |
| Offre | 99,50 | 99,80 | - | 101,74 | 102,20 | 98,50 | - | 102,25 | 96,50 | - | - | 98,98 | 100,34 | 97,97 | 101,16 | 100,60 | - | 99,86 | 101,80 | 101,30 |